Emerging therapeutics that utilize RNA interference (RNAi) have the potential to treat broad
classes of diseases due to their ability to reversibly silence target genes. In August 2018, the …

The highly specific induction of RNA interference-mediated gene knockdown, based on the
direct application of small interfering RNAs (siRNAs), opens novel avenues towards …

Small interfering RNA (siRNA), a 21–23 nt double-stranded RNA responsible for post-
transcriptional gene silencing, has attracted great interests as promising genomic drugs, due …

Therapeutic application of siRNA requires delivery to the correct intracellular location, to
interact with the RNAi machinery within the target cell, within the target tissue responsible for …

Small interfering ribonucleic acids (siRNAs) form potentially the most important class of next
generation therapeutics. However, achieving their efficient delivery in the correct dose, time …

RNA interference (RNAi) has broad potential as a therapeutic to reversibly silence any gene.
To achieve the clinical potential of RNAi, delivery materials are required to transport short …

Cholesterol-conjugated siRNAs can silence gene expression in vivo. Here we synthesize a
variety of lipophilic siRNAs and use them to elucidate the requirements for siRNA delivery in …

Since the discovery of the Nobel prize-winning mechanism of RNA interference (RNAi) ten
years ago, it has become a promising drug target for the treatment of multiple diseases …

Small interfering RNA (siRNA) is a potential method of gene silencing to target specific
genes. Although the US Food and Drug Administration (FDA) has approved multiple siRNA …

With increasing knowledge on the molecular mechanisms of endogenous RNA interference,
small interfering RNAs (siRNAs) have been emerging as innovative nucleic acid medicines …